Here, we found that NKG2D ligands were highly expressed on human prostate cancer cell lines, and our designed NKG2D-based CAR T cells could effectively recognize and lyse NKG2D ligand-positive prostate cancer cells. The gene discussed is KLRK1; the disease is prostate cancer.